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Abstract 
 
This review describes the oculo-visual problems likely to be encountered in 
Parkinson’s disease (PD) with special reference to three questions: (1) are there visual 
symptoms characteristic of the prodromal phase of PD, (2) is PD dementia associated 
with specific visual changes, and (3) can visual symptoms help in the differential 
diagnosis of the parkinsonian syndromes, viz. PD, progressive supranuclear palsy 
(PSP), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), and 
corticobasal degeneration (CBD)? Oculo-visual dysfunction in PD can involve visual 
acuity, dynamic contrast sensitivity, colour discrimination, pupil reactivity, eye 
movement, motion perception, and visual processing speeds. In addition, disturbance 
of visuo-spatial orientation, facial recognition problems, and chronic visual 
hallucinations may be present. Prodromal features of PD may include autonomic 
system dysfunction potentially affecting pupil reactivity, abnormal colour vision, 
abnormal stereopsis associated with postural instability, defects in smooth pursuit eye 
movements, and deficits in visuo-motor adaptation, especially when accompanied by 
idiopathic rapid eye movement (REM) sleep behaviour disorder. PD dementia is 
associated with the exacerbation of many oculo-visual problems but those involving 
eye movements, visuo-spatial function, and visual hallucinations are most 
characteristic. Useful diagnostic features in differentiating the parkinsonian symptoms 
are the presence of visual hallucinations, visuo-spatial problems, and variation in 
saccadic eye movement dysfunction. 
 
Key words: Parkinson’s disease (PD), oculo-visual dysfunction, prodromal phase, PD 
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Introduction 
 
Patients with Parkinson’s disease (PD) can exhibit significant non-motor symptoms 
including apathy [1], depression, sleep problems, cognitive impairment, dementia, 
and autonomic, gastrointestinal, and sensory dysfunction [2]. Sensory problems may 
include oculo-visual dysfunction, loss of smell, auditory problems, and ‘restless legs’ 
syndrome [3]. A variety of oculo-visual problems have been reported in PD including 
defects in primary vision such as visual acuity (VA), colour vision, and eye 
movement, and deficits in more complex visual tasks involving the ability to judge 
distance or the shape of an object [2,4]. Visual deficits in PD are important in 
influencing overall motor function [5], are a risk factor for developing hallucinations 
[6], and can have a significant influence on general quality of life [2].  
 
There is increasing recognition of a prodromal phase which may precede actual 
diagnosis of PD by several years and which could involve non-dopamine as well as 
dopamine-related pathways [7]. In addition, the concept of ‘Parkinson’s disease 
associated risk syndrome’ has been proposed in which at risk patients may possess 
genetic factors which predispose to the disease or exhibit early non-motor risk 
symptoms [8]. Hence, motor features, autonomic system dysfunction, and 
neuropsychological disturbances may occur early in PD [7,9,10]. Some of these 
changes may reflect degeneration of the central and peripheral dopamine 
neurotransmitter systems, early in the disease [11]; the delay between onset of 
dopamine denervation and the appearance of motor symptoms being 5 – 20 years [7]. 
It may be possible to identify potential biomarkers that can detect individuals at an 
early stage of PD thus permitting early intervention and potential neuroprotection 
[10]. Strictly, prodromal disease defines a condition that exists before PD is definitely 
diagnosed, and hence studies of early clinical PD are not directly assessing prodromal 
disease, although such features may ultimately be shown to be present in the 
prodromal phase [12].  
 
Cognitive disturbance can also occur in PD as the disease develops and can vary from 
subtle mental dysfunction to overt dementia [13]. Dementia associated with PD (PD 
dementia) is a particularly debilitating condition, 80% of patients being potentially at 
risk [14]. The risk of PD dementia increases with patient age, 90% of recorded cases 
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being over 70 years of age [15]. In a longitudinal, community-based study of patients 
with newly diagnosed PD, 10% of patients developed dementia at a mean of 3.5 years 
after diagnosis and 57% showed evidence of cognitive impairment, fronto-striatal 
deficits being the most common [16]. The most important predictors of dementia 
were tests of semantic fluency and copying geometric figures, tasks which are 
affected by posterior cortical pathology, and probably associated with non-dopamine 
dysfunction [16]. Gray matter atrophy in PD varies with the extent of cognitive 
impairment [17]. Hence, PD patients with little cognitive impairment exhibit no 
significant differences in atrophy compared with the cognitively unimpaired. By 
contrast, PD patients with mild cognitive impairment exhibit limited atrophy affecting 
temporal, parietal, and frontal cortices as well as the caudate nucleus, hippocampus, 
amygdala, and putamen. In PD dementia, reduced gray matter volume in the 
parahippocampal gyrus, visual cortex, and cingulate gyrus may be additionally present 
[17]. Recently, the presence of olfactory deficits in PD has been linked to an increased 
risk of developing PD dementia [14] although this remains a controversial finding 
[18]. 
 
PD is also a member of a larger group of closely-related motor disorders, viz. the 
‘parkinsonian syndromes’. This group includes progressive supranuclear palsy (PSP) 
[19], dementia with Lewy bodies (DLB) [20], multiple system atrophy (MSA) [21], 
and corticobasal degeneration (CBD) [22]. Differential diagnosis of PD within this 
group can be difficult, especially early in the disease, but where visual signs and 
symptoms are present they may be useful adjuncts to diagnosis [2].  
 
This article reviews the oculo-visual symptomology of PD with special reference to 
three questions: (1) are there visual symptoms characteristic of the prodromal phase 
of the disease, (2) is PD dementia associated with an exacerbation of specific visual 
changes, and (3) can visual symptoms aid the differential diagnosis of the 
parkinsonian syndromes? The molecular and neurotransmitter deficits which may be 
responsible for many of these visual changes are also discussed. 
 
Molecular and neurotransmitter deficits in PD 
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Although dysfunction of the dopamine neurotransmitter system has long been 
associated with the pathophysiology of PD [2,4] accumulating evidence suggests that 
PD is a multisystem degeneration [23]. Dopamine is an important neurotransmitter in 
the retina being present in amacrine cells along the inner border of the inner nuclear 
layer (INL) [24] (Fig 1), and accumulated by interplexiform cells [25]. Two types of 
amacrine cells appear to be involved: (1) type 1 cells which send ascending processes 
to synapse with -aminobutyric acid (GABA) interplexiform cells in stratum 1 of the 
INL and (2) type 2 cells which have dendrites stratifying above those of the type 1 
cells of the inner plexiform layer (IPL). Dopamine may be involved in the 
organisation of the ganglion cell and bipolar cell receptive fields and may modulate 
the physical activity of the photoreceptors [26]. In addition, dopamine is involved in 
the coupling of the horizontal and amacrine lateral system [27]. Thinning of the 
retinal nerve fibre layer (RNFL) has been recorded in PD [28] (Fig 1). In particular, 
significant thinning of INL in parafoveal regions has been observed, especially in 
those patients exhibiting visual hallucinations but without overt signs of dementia 
[29]. 
 
Two main dopamine pathways are present in the brain. First, the striatonigral pathway 
originates in the substantia nigra (cell group A9) and terminates in the striatum 
(caudate nucleus, putamen). Second, two pathways originate in the ventral tegmentum 
(cell groups A8, A10) and project to the nucleus accumbens and limbic system 
(mesolimbic pathway), and frontal cortex (mesocortical pathway).  There are also 
dopamine pathways within the hypothalamus which transmit dopamine to the 
pituitary gland and four pathways connecting the ventral tegmentum to the amygdala, 
hippocampus, cingulate gyrus, and olfactory bulb. Significant dopamine activity is 
largely limited to frontal and limbic areas of cerebral cortex and there is significantly 
less activity in visual cortex [30]. Cerebral metabolic rates for glucose are also 
reduced by up to 23% in primary visual cortex (area V1) of PD patients [31]. 
Reductions in dopamine levels in basal ganglia and frontal cortex may also deplete 
levels in the superior colliculus and therefore could be a factor in the production of 
defective saccades [32]. Dopamine also has a peripheral role in sympathetic ganglia, 
visceral ganglia, and in artery walls. Hence, reductions in dopamine in some of these 
regions could be a factor contributing to eye movement problems and defects in pupil 
reactivity in PD. 
 6 
 
 
There is increasing interest in the clinical effects of the degeneration of cholinergic 
basal forebrain and tegmental pedunculopontine complex projection in PD [33]. 
Across the spectrum of PD, whereas dopamine denervation is frequent in individuals 
with minimal or no cognitive change and increases with more severe cognitive 
impairment, cortical cholinergic denervation is a major degenerative process 
associated with cognitive decline [33]. Moreover, extra-nigral pathway and 
cholinergic deficits are particularly common in PD patients exhibiting ‘freezing of 
gait’ [34]. Nevertheless, cholinergic deficits in PD are variable and may aid selection 
of patients for targeted drug therapies [35].  
 
Third, surviving neurons of the substantia nigra in PD often contain Lewy bodies 
(LB) which differ from other types of neurofibrillary pathology in that they contain 
abnormal aggregates of the protein -synuclein [36]. -Synuclein is a small pre-
synaptic protein and the entire molecule undergoes a conformational change in PD 
resulting in the insoluble protein that forms a major component of the LB. The role of 
-synuclein pathology in PD, however, is controversial. In a large post-mortem study 
of cases with -synuclein pathology in the dorsal motor vagus, substantia nigra, and 
basal forebrain, only 32/106 cases had been diagnosed with a neurodegenerative 
disorder [37]. In addition, neither the distribution nor load of -synuclein permitted 
dependable post-mortem diagnosis of extrapyramidal symptoms or cognitive 
impairment.    
 
Oculo-visual symptoms in PD 
 
The oculo-visual problems that may be present in prodromal PD, in PD generally, and 
most likely to be exacerbated in PD dementia are summarised in columns 2 - 4 of 
Table 1.  
 
Colour vision  
 
Colour vision dysfunction maybe a disease specific feature of PD [38-40] and has 
been suggested as a possible diagnostic sign [41]. Hence, using the Farnsworth-
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Munsell 100-hue test, PD patients frequently exhibit higher error scores that controls 
after age adjustment, the frequency of error scores often correlating with the severity 
of motor symptoms [42].  In addition, vision in PD may be blurred using coloured 
stimuli [43] with reduced perception of monochromatic contours especially for dark-
green, light-blue, and dark-red stimuli [44]. Defective colour vision may also be an 
early sign of dopamine dysfunction in PD [40]. Hence, in 100 idiopathic PD patients, 
27 of whom were expressing PD linked mutations, colour vision was consistently 
impaired [45]. However, other studied suggest that colour vision may not be 
consistently impaired in early PD [46]. Although no overall significant differences 
between PD and controls were present in the study, elevation of error scores 
exceeding the upper limit of normality occurred in three cases. Colour vision deficits 
may be more characteristic of disorders characterised by -synuclein-immunoreactive 
pathology such as PD/DLB [47]. However the pathophysiology of colour 
discrimination deficits in PD is likely to be complex. Hence, cognitive impairment 
can make a major contribution to the degree of colour discrimination deficits in PD 
[48]. In addition, the effect of coloured lights on gait and freezing of gait have been 
investigated in PD, with in a pilot experiment, green light improving gait and 
attenuating freezing of gait better than red or no light [49]. 
 
Visual fields  
 
Few studies of visual field defects have been carried out in PD and there is poor 
evidence for the consistent presence of such deficits [50]. However, there is 
controversy regarding whether there is increased frequency of glaucomatous visual 
field defects in PD [51]. In addition, visual fields were also investigated in patients 
undergoing posterior pallidotomy, a surgical procedure which risks damaging 
structures such as the optic tract [52]. Of 40 such patients, three had visual field 
defects which could have been attributable to the surgery, viz., contralateral superior 
quadrantanopias, associated in two patients with small paracentral scotomas. 
 
Saccadic and smooth pursuit eye movements  
 
Objective assessment of oculomotor function in PD is usually made by electro-
oculography. Electro-oculography responses are often normal in PD patients when the 
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eyes are in the primary position or when resting. Abnormal saccadic and smooth 
pursuit eye movements, however, are well established in PD and reported in about 
75% of patients [53]. Both reaction times and the maximum saccadic velocity of 
horizontal gaze are slower in PD than controls [53]. Saccadic eye movements may 
exhibit hypometria, i.e., 'under reaching of task' [32] while smooth pursuit movements 
may be interrupted by small additional saccades [53]. In addition, the amplitude of 
saccadic eye movements is often increased in normal subjects when there is a change 
from externally cued saccades to self-paced saccades and this effect is often greater in 
PD [54]. In a study in which the delay of remembered (imagined) saccades was 
gradually increased in untreated PD, there was a marked hypometria of saccadic gain 
at all delays suggesting dysfunction of the striato-collicular inhibitory pathway 
resulting from dopamine deficiency in the basal ganglia [53]. In addition, spatial 
working memory was studied in relation to eye movements [55,56] in which a 
sequence of four targets was memorised by the patient and then the eyes were moved 
to fixate the targets in their correct order. In PD, several discrete saccadic eye 
movements of reduced amplitude were necessary before reaching the final eye 
position and the patients also exhibited an increase in errors while remembering the 
target sequence.  
 
Electro-oculography recordings have also been made before and after apomorphine 
treatment in early stage patients suggesting that smooth pursuit movements could be 
affected during the prodromal phase [57]. In addition, patients with PD often have 
difficulty in sustaining repetitive actions and hence, smooth pursuit movements 
exhibit a reduction in response magnitude and a progressive decline of response with 
stimulus repetition. 
 
Stereopsis  
 
Impairment of stereopsis (‘depth perception’) can be observed in PD associated with 
impaired VA and colour perception [58,59], and has been attributable to pathology in 
extrastriate cortical areas [60]. Stereopsis is mediated by various neural pathways 
involving the thalamus and posterior parietal lobe, areas likely to be affected in PD 
and especially in PD dementia, as the pathology spreads to posterior parietal regions.  
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Nystagmus and convergence 
 
Abnormal optokinetic nystagmus ('train nystagmus'), an abnormal rhythmical 
movement of the eyes, induced when a patient looks at a moving object [53], and 
poor convergence, i.e., the ability of both eyes to fixate a common point [61], have 
both been reported in PD and are also important signs in PSP. Convergence can be 
associated with a relatively large outward deviation of the eye (exophoria), and the 
result is often double vision [62]. 
 
Eyelids 
 
Eyelid problems in parkinsonian syndromes can seriously impair vision as a result of 
difficulties in opening the lids after voluntary closure (‘apraxia of eyelid opening’) 
[63]. Apraxia of eyelid opening can occur at the onset of disease [64] and the 
condition may worsen if the patient is given L-dopa as a possible treatment. The 
problem is likely to be attributable to a loss of the reciprocal relationship between the 
levator palpebrae and the pretarsal portion of the orbicularis oculi muscles, both of 
which contract together in PSP rather than exhibiting their normal opponent action. In 
addition, involuntary eyelid closure can occur after deep brain stimulation of the 
subthalamic nucleus in PD, implicating this region in pathophysiology [65]. 
 
A reduced frequency of blinking leading to a staring appearance is common in PD 
[60]. Reduced blink rates can also lead to an abnormal tear film, dry eye, and reduced 
vision. A characteristic ocular sign of PD is the blink reflex, elicited by a light tap 
above the bridge of the nose, successive taps in normal individuals producing less and 
less response as the reflex habituates [66]. In PD, the blink reflex may not disappear 
on repeated tapping. In addition, blink duration may be increased in PD and may be a 
consequence of the increasing loss of dopamine neurons [67]. The blink reflex is 
mediated by: (1) the nasociliary branch of the trigeminal nerves which senses the 
stimulus, (2) the temporal and zygomatic branches of the facial nerve which initiate a 
motor response, and (3) a number of nuclei in the pons. Hence, the pathophysiology 
of the blink reflex in PD is likely to be complex [68] with dopamine dysfunction in 
frontal lobes [69] and a reduction in the inhibitory effect of the nucleus reticularis 
giganto cellularis as possible contributory factors [70]. 
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Pupil reactivity 
 
Significantly larger pupil diameters, with unequal pupil sizes (anisocoria) after light 
adaptation, have been reported in PD [71], no such differences being apparent after 
dark adaptation. In addition, longer light reflex latencies and constriction times have 
been observed while contraction amplitudes may be reduced [66]. These results 
suggest autonomic imbalance in PD involving the parasympathetic system. 
Autonomic dysfunction can be an early manifestation of PD [72] and therefore, 
changes in pupil reaction could be present in the prodromal phase. In addition, the 
maximum contraction ability of the iris muscle measured in vitro is greater in PD than 
in controls suggesting that the muscle may have acquired adaptive sensitivity changes 
[73]. 
 
Contrast sensitivity 
 
Patients with PD and PD dementia frequently complain of poor vision especially as 
the disease progresses [74,75]. In addition, contrast sensitivity function (CSF) is 
affected in a proportion of PD patients [76,77], performance at high or intermediate 
frequencies being the most common. In some individuals, a substantial decrease in 
CSF occurs with disease progression which could explain reports of poor vision in 
PD. Abnormalities in CSF could be related to dopamine dysfunction in the retina, but 
are often orientation specific, suggesting cortical involvement [78]. Treatment with L-
dopa can improve CSF performance in PD close to that of controls while treatment 
with apomorphine significantly improves non-colour spatial CSF at all frequencies 
[79]. 
 
Motion detection 
 
Decreased sensitivity to temporally changing stimuli may also occur in PD and is 
especially well demonstrated by studies of the auditory system. Hence, in 
psychophysical tests assessing auditory processing, bilateral subthalamic nucleus 
stimulation caused dysfunction in ability to track rapid fluctuations in sound intensity 
[80]. In addition, in motor tasks involving finger tapping, PD patients were impaired 
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both in the motor task itself and in assessing its duration implicating pathology in 
basal ganglia and the thalamocortical connections involved in timing [81]. 
Subsequently, the substantia nigra was shown to be involved in temporal processing 
involving motor and perceptual tasks [82]. Hence, there could be deficits in the visual 
perception of rapidly moving stimuli in PD which could potentially cause problems in 
tracking fast moving targets. 
 
Electroretinogram 
 
The amplitude of the electroretinogram 'b' wave is reduced in PD under a variety of 
light conditions [83]. The amplitude of the 'b' wave may be an indicator of INL 
function and therefore, its reduction may reflect defects in visual processing involving 
dopamine neurons. The amplitude of the pattern response electroretinogram (PERG) 
to a checkerboard stimulus is also decreased in PD [83] and the latency of the P50 
component delayed [84]. Subsequent studies have suggested that retinal dopamine 
depletion may result in attenuated electroretinogram responses to peak stimuli [85]. In 
addition, steady-state pattern PERG to sinusoidal gratings was studied over a range of 
spatial frequencies [86]. Aging affected responses at all spatial frequencies but the 
pattern of age-related loss was different in PD. In PD, a specific deficit at medium 
spatial frequencies was present accompanied by a distorted PERG spatial frequency 
response function. PERG is also sensitive to dopamine manipulation in the monkey 
retina [87]. In an experiment involving the use of a selective D2 antagonist, treatment 
affected the PERG to a sinusoidal vertical grating presented at four spatial frequencies 
[87]. Hence, dopamine appears to be involved in retinal processing and the D2 
receptor to be necessary for spatial-temporal tuning of pattern vision. Subsequently it 
was shown that the two dopamine receptors D1 and D2 play different roles in retinal 
function and therefore affect vision differently in PD [88]. Hence, PERG could be 
useful both in evaluating retinal dopamine mechanisms and in monitoring dopamine 
therapies in PD. 
 
Visual evoked potentials (VEP) 
 
Visual evoked potentials (VEP) in response to coloured stimuli are affected in PD 
[89] Hence, in some patients, amplitude is decreased and latency increased for all 
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chromatic stimuli and especially for those using blue-yellow horizontal gratings [90]. 
Increased latency of the VEP P100 component to a checkerboard stimulus has also 
been reported in PD suggesting a delay in visual processing at one or more stages of 
the visual system [91-93]. As there is significantly less dopamine activity in visual 
cortex, these responses are likely to be related to other neurotransomitters such as the 
cholinergic system..  
 
Complex Visual Functions 
 
Perceptual abnormalities in PD may result from dopamine dysfunction in the retina 
(‘bottom-up’) or can be attributable to deficiencies in attention due to dysfunction of 
the striato-frontal system (‘top-down’) [94]. Hence, mild PD is associated with little 
perceptual abnormality, moderate PD with top-down abnormalities, and more severe 
PD with both types of abnormality, data which suggest retinal effects on perception 
occur later in the disease [94]. In addition, the presence of visuo-perceptual 
impairment could be an indication of developing PD dementia [13]. 
 
There are also prominent deficits in PD involving neuropsychological tests requiring 
self motivation and a demanding response from the patient [1]. Hence, PD patients 
may exhibit a variety of deficits in visuo-spatial orientation [95,96] including 
difficulty in judging verticals and the position of body parts, and in carrying out a 
route-walking task. Visuo-spatial working memory also appears to be selectively 
impaired in early PD which probably reflects degeneration of the basal ganglia, the 
dorsal visual stream, and the frontal-prefrontal cortex [1]. In a problem solving task 
involving arranging coloured balls in pockets on a computer screen, PD patients made 
more errors than controls and also did not show any dissociation in the amount of 
time fixating the two halves of the display [97]. The results suggested difficulties in 
encoding and/or maintaining current goals during problem solving in PD.  
 
Studies also suggest deficits in visuo-motor adaptation early in the disease [98]. 
Hence, in two tasks carried out over three days involving mirror reading and reversed 
vision using a prism, mirror reading time was increased after one day and there was 
significantly more slowing on the reversed vision task in early PD, neither effect 
being correlated with the Wechsler memory score of the patient [98]. In addition, 
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motor adaptation to imposed visual rotation was significantly enhanced when tested 
days later after a sleep-dependent memory consolidation, PD patients and controls 
showing similar movements and adaptation to rotation [99]. After a few days, 
however, PD patients did not show this consolidation.  
 
PD patients also show an impairment of orientation and motion discrimination [100], 
tasks most likely to involve the visual cortex. In addition, impairments in the ability to 
perceive and imagine faces have been reported in PD [101]. Medicated and non-
medicated patients exhibit facial recognition problems but these deficits are most 
frequently present in the untreated group [102]. In addition, normal subjects contract 
their facial muscles while imaging faces, a process which is often impaired in PD.  
 
Visual hallucinations 
 
Visual hallucinations are a chronic complication of PD [103,104] especially in 
patients treated with L-dopa and dopamine agonists and those diagnosed with PD 
dementia. In a large study of PD patients, hallucinations occurred in the previous 
three months in 40% of patients examined, being visual in 22% and auditory in 10% 
of patients [103]. Patients with minor hallucinations had higher depression scores 
than those without. A number of factors were the best predictors of hallucinations, 
viz., a severe cognitive defect, daytime somnolence, longer duration of disease, poor 
vision, and reduced activity in primary visual cortex [31]. Hallucinations in PD are 
often complex with flickering lights, and illusionary misconceptions often preceding 
the most common manifestation, viz., stereotypical colourful images [104].  
 
Is vision affected in the prodromal stage? 
 
A number of oculo-visual features observed in early PD could be present in the 
prodromal phase of PD (Table 1). First, autonomic system dysfunction is well 
documented in early PD [72] and could affect pupil reactivity, and is a feature 
requiring further investigation. Second, electro-oculographic recordings have been 
made before and after apomorphine treatment confirming that smooth pursuit 
movements can be affected during the initial stages [57]. Third, deficits in colour 
vision may occur early in the disease [40]. Fourth, deficits in visuo-motor adaptation 
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may occur during the early stages [98]. Fifth, in PD cases in which idiopathic rapid 
eye movement (REM) sleep behaviour disorder is accompanied by abnormal 
stereopsis, postural instability may be an additional feature [105]. The presence of any 
of these features in undiagnosed individuals may raise a concern of possible PD. 
Since early diagnosis may enable intervention and possible neuroprotection [10], 
further visual studies of the early stage PD are urgently needed.  
 
Is vision specifically affected in PD dementia? 
 
Many of the oculo-visual features present in early and middle stage PD will become 
more severe if the patient develops PD dementia. However, some features appear to 
be particularly exacerbated in PD dementia including deficits in colour vision [47] 
and changes in pupillary function [73,106] (Table 1). In addition, there are visual 
features which may be particularly characteristic of PD dementia. First, prominent 
visual hallucinations are significantly more frequent in PD dementia than PD [107-
110]. Second, severe eye movement problems are more likely to be present in PD 
dementia and to become more extensive with declining cognitive function [111,112]. 
Third, defects in visuospatial orientation are likely to be greater in PD dementia 
especially when associated with greater cortical atrophy [113]. Many additional visual 
features, already detected in PD, are likely to be present in a more severe form in PD 
dementia. 
 
Can oculo-visual symptoms aid differential diagnosis? 
 
Many of the parkinsonian syndromes have overlapping clinical features (Table 1) 
making differential diagnosis difficult. In patients with unclassifiable or with 
indeterminate parkinsonian symptoms, however, the presence of visual hallucinations 
is an important symptom which may indicate underlying LB pathology, i.e., 
supporting a diagnosis of PD/DLB rather than PSP/CBD or MSA [109]. 
 
Dementia with Lewy bodies (DLB)
  
 
A recent review of PD carried out by the ‘International Parkinson’s disease and 
Movement Disorders Societies’ has identified considerable heterogeneity within the 
 15 
 
disease, has questioned the role of classic -synuclein pathology in pathophysiology, 
and considers whether PD and DLB should continue to be regarded as distinct 
disorders [114]. Separating PD from DLB was thought to be important because 
patients with visual hallucinations may be treated with antipsychotic drugs, regarded 
as a hazardous treatment in DLB [115]. In addition, DLB patients were thought to 
exhibit fewer tremors, more asymmetry of motor symptoms, more falls, and respond 
less well to dopamine treatment than PD [110]. DLB and PD patients, however, 
exhibit similarities on a variety of saccadic eye movement tasks. A newly developed 
portable saccadometer has been used to compare saccadic latency distribution in 
several parkinsonian syndromes [116] suggesting that a combination of saccadic 
parameters could discriminate between PD and DLB better than any single parameter. 
Although there are similarities in general cognitive performance in PD and DLB there 
may also be subtle differences. For example, deficits in orientation, ‘trail-making’, 
and reading the names of colours (‘Stroop test’) suggest DLB rather than PD [117]. 
Visual perception tasks (visual discrimination, space-motion and object-form 
recognition), however, are usually equally impaired in DLB and PD, especially in 
patients with visual hallucinations [111]. Cognitive/psychiatric symptoms including 
overt dementia are generally less frequent in PD than in DLB [118]. However, it is 
likely that these differences reflect heterogeneity within PD or the presence of distinct 
disease subtypes of PD. 
 
Progressive supranuclear palsy (PSP) and cortico-basal degeneration (CBD) 
 
PSP and CBD are both four-repeat (4R) tau diseases exhibiting considerable 
similarities and overlap [19,22]. Distinguishing PD from PSP can be especially 
difficult early in the disease. Atypical features of PSP include slowing of upward 
saccades, moderate slowing of downward saccades, the presence of a full range of 
voluntary vertical eye movements, a curved trajectory of oblique saccades, and 
absence of square-wave jerks [119]. Hence, particularly useful in separating PSP from 
PD is the presence in the former of vertical supranuclear gaze palsy, fixation 
instability, lid retraction, blepharospasm, and apraxia of eyelid opening and closing 
[120]. Downgaze palsy is probably the most useful diagnostic clinical symptom of 
PSP [121]. Deficits in colour vision appear to be more important in PD and directly 
related to the dopamine system. However, in untreated early PD, no consistent deficits 
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in colour vision were demonstrated making this alone an unreliable indicator of PD 
[46]. 
 
By contrast, typical oculo-visual features of CBD include increased latency of 
saccadic eye movements [122-124], impaired smooth pursuit movements [122], and 
visuo-spatial dysfunction especially involving object-based tasks [125]. Less typical 
features include vertical gaze palsy, visual hallucinations, sleep disturbance, and an 
impaired ERG. It is also possible that visuospatial deficits are more prominent in 
CBD, a mixed cortical/subcortical dementia, than in PD dementia.  
 
Multiple system atrophy (MSA) 
 
Anderson et al. [126] suggest several features suggestive of MSA including excessive 
square-wave jerks, mild to moderate hypometria of saccades, impaired vestibulo-
ocular reflex (VOR), and the presence of nystagmus. In addition, visual 
hallucinations, unrelated to medication, are rare in MSA compared with PD and their 
presence can often exclude MSA as a possible diagnosis [127]. In addition, there is 
greater retinal pathology in PD, which results in significant defects in dynamic CSF 
and in the early components of the VEP, which are not likely to be present in MSA. 
Moreover, the colour VEP is affected in PD but not in MSA [128]. Nevertheless, 
where defects in the VEP occur in MSA, they are more likely to involve more 
complex event-related potentials and components such as the P300 [129,130]. A 
feature which may be useful in separating PD and MSA is an ability to fixate an 
object, which is abnormal in a significant proportion of patients with MSA but less so 
in PD [131]. In addition, eye movements recorded during sinusoidal tracking by 
video-oculography show that in MSA, saccades correct for position error (‘catch-up 
saccades’) while in PD, saccades are directed towards future target positions 
(‘anticipatory saccades’) [132]. 
 
In conclusion, PD can affect visual acuity, CSF, colour discrimination, pupil 
reactivity, eye movement, motion perception, and visual processing speeds. 
Disturbances of visuo-spatial orientation, facial recognition problems, and chronic 
visual hallucinations may also be present. Possible prodromal features of PD include 
autonomic system dysfunction which could affect pupil reactivity, abnormal colour 
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vision and stereopsis, the latter associated with postural instability, and abnormal 
smooth pursuit eye movement function. PD dementia is associated with the 
exacerbation of many of the oculo-visual problems present in PD generally but those 
involving eye movements, visuo-spatial function and visual hallucinations appear 
most characteristic. Useful diagnostic features in differentiating the parkinsonian 
symptoms are the presence/absence of visual hallucinations, visuo-spatial problems, 
and variation in saccadic eye movement dysfunction 
. 
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Table 1. Comparison of oculo-visual dysfunction in Parkinson’s disease (PD) and 
other parkinsonian syndromes.  
     Disorder 
_____________________________________________________________________ 
Feature  PR PD PD-Dem DLB PSP CBD MSA 
_____________________________________________________________________ 
Visual acuity   +/-   - 
Colour vision  +/- + +  +  - - 
Stereopsis  + + +    
Contrast sensitivity  +    +  - 
Motion detection  +     
Visual fields   +   +  + 
Eyelid mobility  +    + + - 
Blink reflex   +     + 
Pupil reactivity +/- + +  + +  + 
Fixation       +  + 
Saccadic EM   + +  + + + + 
Smooth pursuit EM + + +   + + + 
Nystagmus   +
on
    +
on
 +
on
 + 
VOR        + +/- +  
ERG    +
f
   +
f
 +  +/- 
Cortical VEP   +
Ch
    -  -  
Visuo-spatial  + + +  +  + - 
function 
Visuo-motor  + + 
adaptation 
Reading ability     + +  + 
Object recognition  +
fa
   + 
Visual hallucinations  + +  + +
r
 +
r
 +
r
 
_____________________________________________________________________ 
Abbreviations: Disorders: PR = Prodromal phase of disease, PD = Parkinson’s 
disease without dementia, PD-Dem = Parkinson’s disease with dementia DLB = 
Dementia with Lewy bodies, PSP = Progressive supranuclear palsy, CBD = 
Corticobasal degeneration; MSA = Multiple system atrophy, Visual features: EM = 
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Eye movements, EP = Evoked potential, ERG = Electroretinogram, VEP = Visual 
evoked potential; Symbols: Unaffected (-), Affected (+), Controversial (+/-). 
Superscripts: Ch = Chromatic VEP, f = Flash VEP, fa = Faces, on = Abnormal 
optokinetic nystagmus, r = rarely present Blanks indicate where limited available data 
to assess visual function. PD dementia data include only features where there is 
evidence suggesting exacerbation with developing cognitive dysfunction.  
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Legends to figures 
 
Fig 1. Retinal image of a normal control subject using optical coherence tomography 
(OCT) showing the various functional layers: Fo = Location of fovea, NFL = Nerve 
fibre layer, GCL = Ganglion cell layer, IPL = Inner plexiform layer, INL = Inner 
nuclear layer, OPL = Outer plexiform layer, ONL = Outer nuclear layer, RPE = 
Retinal pigment epithelium, PR = Photoreceptor layer, N = Nasal direction, T = 
Temporal direction. A specific thinning of INL in the parafoveal region has been 
recorded in Parkinson’s disease (PD). (Image courtesy Dr R Heitmar, Aston 
University) 
 
 
 
 
 
